# Bremelanotide (Vyleesi)

> Melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women.

Source: https://peptides.cafe/peptide/bremelanotide-vyleesi
Category: Melanocortin Agonist · Sexual Health
Tag: FDA-Approved · Sexual Health

## Mechanism
Cyclic 7-amino-acid synthetic analog of α-MSH that activates melanocortin receptors (primarily MC4R) in the CNS, modulating sexual desire pathways.

## Research areas
- Acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women

## Common research protocols
- On-demand: 1.75 mg SC at least 45 minutes before anticipated sexual activity (max 1 dose/24h, 8/month).

## Study summaries
- "RECONNECT trials" — Obstetrics & Gynecology (2019): Improved desire and reduced distress vs placebo in premenopausal HSDD.

## Considerations
- FDA-approved.
- Nausea, flushing, transient BP elevation common.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.